Condition: Germ Cell Tumor · Sponsor: Indiana University
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
This description comes directly from the study's public registry record.
Jennifer King, MD · 317-948-0361 · jmstrass@iu.edu
Christin Snow, RN · 317-274-5830 · chsnow@iu.edu
Always discuss trial participation with your own doctor first.
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06937866